13F reference period
Q2 2026
Security Snapshot
Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) Institutional Ownership
CUSIP: 002942100
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
71
Shares (Excl. Options)
9.43M
Full value: 9,430,441 · shares · 30 Jun 2026Price
$5.76
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share (the "Shares")
- Symbol
- AARD on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 9,430,441
- Total 13F value
- $54,337,990
- Portfolio coverage rank
- 0%
- Share change
- -769,223
- Value change
- -$3,027,649
- Number of holders
- 71
- Shares outstanding
- 21,303,054
- SEC-reported price per share
- $4.96
- Insider filing price
- $4.96
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") is tracked under CUSIP 002942100.
- 71 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 77 to 71 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$38.45M
Full value: $38,449,918 · USD · 31 Mar 2026.$54.34M
Full value: $54,337,990 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 71 institutions filings for Q2 2026.
Security key
002942100
13F reference period
Q2 2026
13F holders
71
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
AARD full holder history
Aardvark Therapeutics, Inc. SEC filings
Aardvark Therapeutics, Inc. company facts
Aardvark Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 002942100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AARD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lee Tien-Li | 14% | $34,103,965 | 2,983,724 | Tien-Li Lee | 31 Mar 2025 | |||
| Tan Finian | 9.6% | $23,441,810 | 2,050,902 | Vickers Venture Fund VI Pte. Ltd. | 12 Feb 2025 | |||
| CITADEL ADVISORS LLC | 5.6% | $13,635,659 | 1,192,971 | Kenneth Griffin | 14 Feb 2025 |
As of 30 Jun 2026,
71
institutional investors reported holding
shares of
Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD).
This represents
44%
of the company’s total
outstanding shares.
9.43M
Full value: 9,430,441 · shares · 30 Jun 202621.3M
Full value: 21,303,054 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
43%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Decheng Capital LLC | 18% | 3,917,299 | 0% | 3.1% | $22,563,642 |
| CITADEL ADVISORS LLC | 6% | 1,283,166 | +3.2% | 0% | $7,391,037 |
| Laurion Capital Management LP | 4.9% | 1,034,459 | 0% | 0.43% | $5,958,484 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 562,877 | +1.6% | 0% | $3,242,172 |
| AQR CAPITAL MANAGEMENT LLC | 2.3% | 480,249 | +257% | 0% | $2,766,234 |
| EcoR1 Capital, LLC | 1.9% | 396,194 | 0.11% | $2,282,077 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.4% | 300,000 | 0% | 0% | $1,728,000 |
| BlackRock, Inc. | 0.88% | 187,045 | -76% | 0% | $1,077,378 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.7% | 149,844 | -52% | 0% | $863,529 |
| CANTOR FITZGERALD, L. P. | 0.55% | 116,582 | +75% | 0.01% | $671,512 |
| TWO SIGMA INVESTMENTS, LP | 0.51% | 108,377 | -34% | 0% | $624,252 |
| RAYMOND JAMES FINANCIAL INC | 0.37% | 79,284 | +628% | 0% | $456,676 |
| VANGUARD FIDUCIARY TRUST CO | 0.35% | 75,172 | -9.7% | 0% | $432,991 |
| Woodline Partners LP | 0.34% | 72,429 | 0% | 0% | $417,191 |
| MILLENNIUM MANAGEMENT LLC | 0.33% | 69,948 | -29% | 0% | $402,900 |
| STATE STREET CORP | 0.28% | 59,273 | -70% | 0% | $341,412 |
| J. Goldman & Co LP | 0.19% | 40,500 | 0.01% | $233,280 | |
| IEQ CAPITAL, LLC | 0.18% | 38,382 | +133% | 0% | $221,080 |
| UBS Group AG | 0.17% | 35,639 | -77% | 0% | $205,281 |
| MORGAN STANLEY | 0.14% | 30,177 | +72% | 0% | $173,820 |
| NORTHERN TRUST CORP | 0.13% | 28,080 | -68% | 0% | $161,741 |
| CITIGROUP INC | 0.12% | 26,299 | -43% | 0% | $151,482 |
| Cresset Asset Management, LLC | 0.11% | 24,033 | -44% | 0% | $138,430 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.11% | 24,025 | 0% | $138,384 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.11% | 24,000 | -11% | 0% | $138,240 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,052,255 | $5,545,705 | -$81,674 | $5.27 | 14 |
| 2026 Q2 | 9,430,441 | $54,337,990 | -$3,027,649 | $5.76 | 71 |
| 2026 Q1 | 10,199,105 | $38,449,918 | -$10,262,158 | $3.77 | 77 |
| 2025 Q4 | 10,747,406 | $141,005,712 | +$11,023,600 | $13.12 | 65 |
| 2025 Q3 | 9,460,972 | $125,736,962 | +$6,781,972 | $13.29 | 48 |
| 2025 Q2 | 8,915,770 | $120,541,916 | +$8,913,830 | $13.52 | 35 |
| 2025 Q1 | 8,686,452 | $65,110,057 | +$64,849,535 | $7.51 | 27 |